Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

By Bernard R. Chaitman, C. Pepine, J. Parker, Jaroslav Skopal, G. Chumakova, J. Kuch, Whedy Wang, S. Skettino, A. Wolff. Journal of the American Medical Association (JAMA), 2004

676 citations recorded by the source corpus.

Subfields: Anesthesiology and Pain Medicine, Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/96618ce63546d858c414a64c1593a61b47db019e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Hani Jneid
2. G. Lopaschuk
3. Allan S. Jaffe

Citations in the corpus

• Adaptive designs in clinical trials: why use them, and how to run and report them (2018, methodology): “A trial with blinded sample size re-estimation Combination Assessment of Ranolazine in Stable Angina (CARISA) was a multi-centre randomised double-blind trial to investigate the effect of ranolazine on the exercising capacity of patients with severe chronic angina [30].”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Ranolazine Ranolazine is an antianginal medication with minimal effects on heart rate and BP.(260,261) It inhibits the late inward sodium current and reduces the deleterious effects of intracellular sodium and calcium overload that accompany myocardial ischemia.”
• Myocardial substrate metabolism in the normal and failing heart. (2005, background): “It is important to note that partial inhibitors of myocardial fatty acid oxidation have been shown to lessen ischemic dysfunction and tissue damage in animal models of ischemia and reperfusion and have clear benefits in clinical trials in patients with chronic stable angina (26, 50, 78, 195, 340, 40”